GlassScriptPhysician profile
Bezawit Tekola
NPI 1770742595
$8,232.11
in general payments reported to CMS, 2019-2025
44 companies · $1,986 in 2025
The $1,986 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $454 · 2021: $513 · 2022: $1,500 · 2023: $1,316 · 2024: $1,423 · 2025: $1,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,725.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,751.53 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,093.98 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $981.61 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $721.66 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $674.14 | 2019-2025 | |
| Gilead Sciences, INC. | $481.21 | 2019-2025 | |
| Celgene Corporation | $405.98 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $187.03 | 2020-2023 | |
| Qol Medical, LLC | $148.52 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $132.39 | 2022-2025 | |
| Braintree Laboratories, INC. | $122.39 | 2022-2025 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $121.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $99.39 | 2024-2025 | Omvoh |
| Ucb, INC. | $96.85 | 2019 | |
| Ironwood Pharmaceuticals, INC | $95.87 | 2019-2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $91.86 | 2024-2025 | Vowst |
| Phathom Pharmaceuticals, INC. | $90.04 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $87.20 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $85.91 | 2024 | Iqirvo, Bylvay |
| Intercept Pharmaceuticals, INC. | $79.98 | 2023-2025 | Ocaliva |
| Ardelyx, INC. | $76.71 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $67.40 | 2021-2023 | Rebyota |
| Alnylam Pharmaceuticals INC. | $66.06 | 2024-2025 | Givlaari |
| Echosens North America, INC. | $53.01 | 2024 | Fibroscan |
| Amgen INC. | $52.20 | 2020-2023 | Avsola, Amjevita |
| Boston Scientific Corporation | $46.39 | 2019-2020 | |
| Daiichi Sankyo INC. | $41.29 | 2020-2023 | Injectafer |
| Shionogi INC | $36.03 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $34.14 | 2025 | Monoferric |
| Enterra Medical, INC. | $27.08 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.64 | 2023 | Cyltezo |
| Novo Nordisk INC | $24.93 | 2025 | Wegovy |
| Orphalan INC | $24.83 | 2025 | Cuvrior |
| Fresenius Kabi USA, LLC | $22.74 | 2023 | Idacio |
| Regeneron Healthcare Solutions, INC. | $19.88 | 2025 | Dupixent |
| Medtronic, INC. | $17.88 | 2025 | Interstim |
| Cumberland Pharmaceuticals, INC. | $16.43 | 2019 | |
| Capsovision, INC. | $15.04 | 2024 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $14.63 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bezawit Tekola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.